Prostate Cancer News and Research

Latest Prostate Cancer News and Research

CAP meeting to highlight medical diagnostic procedures

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP).

24 Sep 2010

Data shows preoperative Web-based interactive programs reduce hospital stays

Patients who participate in Web-based interactive programs prior to surgery have a significantly shorter length of stay than those who do not, according to new data. Preoperative education reinforces messages about care instructions and safety, and reduces the level of stress patients experience after their procedure - leading to improved efficiency and care.

23 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

First Edition: September 21, 2010

In today's headlines, news about major insurers' plans to stop offering child-only health policies in advance of new rules.

21 Sep 2010

Prostate cancer - TRAIL is worth a trial

One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.

21 Sep 2010

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Global dementia costs hit $604 billion: World Alzheimer Report 2010

The total estimated worldwide costs of dementia are $604 billion in 2010, according to the newly released World Alzheimer Report 2010, The Global Economic Impact of Dementia from Alzheimer's Disease International (ADI), a London based, nonprofit, international federation of 73 national Alzheimer organizations, including the Alzheimer's Association (U.S.).

21 Sep 2010

Crestor suppressed human cancer cells transplanted to mice

A drug commonly prescribed for people with high cholesterol may also be effective in treating prostate cancer, according to new research by Dr. Xiao-Yan Wen at St. Michael's Hospital.

20 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

CBC members, patient advocacy organizations offer support for PRIME Act

In a presentation today at the Congressional Black Caucus Foundation's Annual Legislative Conference Health Braintrust meeting, Faina Shtern, M.D., president and CEO of AdMeTech Foundation, unveiled overwhelming support from Congressional Black Caucus members and patient advocacy organizations for the Prostate Research, Imaging, and Men's Education Act of 2010.

18 Sep 2010

PCF applauds new prostate cancer legislation

As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana.

17 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010